knowledge -WSS

knowledge

author：hotspot 2025-10-01 17:34:50 - browse：4141

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： The explosion of genetic testing requires a new approach

WSS

STAT Summit: GSK CEO on pharma giant's new direction

Beam Therapeutics to lay off 20% of its staff, re

'The boss' wants server deleted: New allegations emerge in Trump indictment

Beam Therapeutics to lay off 20% of its staff, re

Researchers explore possible ties between long Covid, menopause

Will biotech layoffs continue through 2023?

hotspot

knowledge

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ending health disparities requires full federal government, panel says

Supreme Court strikes down use of affirmative action

Interest rates are at a 22

Trump demands the U.S. pay no more for drugs than other countries … again

Beam Therapeutics to lay off 20% of its staff, re

DIEP, the 'gold standard' of breast reconstruction, is under threat

First Opinion Podcast: Long Covid needs a new approach

Sports medicine is finally prioritizing gender equality

FDA warns J&J's Abiomed: We will regulate your software

focus

Biden announces an advanced cancer research initiative

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

VC firm RA Capital starts a new synthetic biology incubator

STAT Summit: Biotech founders on deal

Ford recalls 870K F

Researchers explore possible ties between long Covid, menopause

explore

focus

knowledge

explore